Eli Lilly to Acquire Dice Therapeutics for $2.4 Billion in Autoimmune Treatment Push

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

Related Keywords

Eli Lilly ,Patrik Jonsson ,Dice Therapeutics ,San Francisco Based ,